MedTrace Logo

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

NCT01511874 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2015-09-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.

Conditions

Interventions

DRUG

ELIGARD 22.5mg

a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks

Sponsors & Collaborators

  • HanAll BioPharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Byung Ha Chung, Medicine · Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-05-31
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511874 on ClinicalTrials.gov